Peanut Allergy clinical trials at UCLA
3 in progress, 0 open to eligible people
Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Sorry, in progress, not accepting new patients
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Los Angeles, California and other locations
Biologics to Improve Multi OIT Outcomes (COMBINE)
Sorry, in progress, not accepting new patients
Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.
Los Angeles, California and other locations
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Sorry, in progress, not accepting new patients
Open-label, follow-up study for subjects who completed the EPITOPE study.
Los Angeles, California and other locations
Our lead scientists for Peanut Allergy research studies include Maria Garcia-lloret.
Last updated: